he just ought to be more precise, he doesn't need to go. to those who say we're interpreting things oddly, no "we're" not. it's as clear as day when something like ICON goes through and GC has to note "not a classic partnership." he is modifying something he said that was generally accurate. this is true on other fronts. now, CEOs shouldn't be so hamstrung that they can't tell us anything, and they need to be flexible enough to adapt to new deals conditions etc. Also, please note from the update that in the same partnership breath he says "at the current time" when referring to maintaining lympro rights, and still on aug 10 said after lp-002 they expect a partnership. taken together, and with the unexpected style of CLIA parter, that still leaves door open for additional business activity around lympro once we get lp-002 data either further involving icon or another party, so i'm not ruling out announcements by 9/22. it's not clear right now, and because we did get a partnership/partnership-substitute, that may be it for now and i.m.o he kept his "word" (can't believe that debatable) and we still own all lympro which could prove very beneficial. let the boys play!
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links